Literature DB >> 25653151

Saccharomyces boulardii CNCM I-745 reduces the duration of diarrhoea, length of emergency care and hospital stay in children with acute diarrhoea.

E C Dinleyici1, A Kara, N Dalgic, Z Kurugol, V Arica, O Metin, E Temur, O Turel, S Guven, O Yasa, S Bulut, G Tanir, A S Yazar, A Karbuz, M Sancar, M Erguven, G Akca, M Eren, M Ozen, Y Vandenplas.   

Abstract

Evidence from the literature has shown that Saccharomyces boulardii provides a clinically significant benefit in the treatment of acute infectious diarrhoea in children. In this multicentre, randomised, prospective, controlled, single blind clinical trial performed in children with acute watery diarrhoea, we aimed to evaluate the impact of S. boulardii CNCM I-745 in hospitalised children, in children requiring emergency care unit (ECU) stay and in outpatient settings. The primary endpoint was the duration of diarrhoea (in hours). Secondary outcome measures were duration of hospitalisation and diarrhoea at the 3(rd) day of intervention. In the whole study group (363 children), the duration of diarrhoea was approximately 24 h shorter in the S. boulardii group (75.4±33.1 vs 99.8±32.5 h, P<0.001). The effect of S. boulardii (diarrhoea-free children) was observed starting at 48 h. After 72 h, only 27.3% of the children receiving probiotic still had watery diarrhoea, in contrast to 48.5% in the control group (P<0.001). The duration of diarrhoea was significantly reduced in the probiotic group in hospital, ECU and outpatient settings (P<0.001, P<0.01 and P<0.001, respectively). The percentage of diarrhoea-free children was significantly larger after 48 and 72 h in all settings. The mean length of hospital stay was shorter with more than 36 h difference in the S. boulardii group (4.60±1.72 vs 6.12±1.71 days, P<0.001). The mean length of ECU stay was shorter with more than 19 h difference in the probiotic group (1.20±0.4 vs 2.0±0.3 days, P<0.001). No adverse effects related to the probiotic were noted. Because treatment can shorten the duration of diarrhoea and reduce the length of ECU and hospital stay, there is likely a social and economic benefit of S. boulardii CNCM I-745 in adjunction to oral rehydration solution in acute infectious gastroenteritis in children.

Entities:  

Keywords:  Saccharomyces boulardii CNCM I-745; acute diarrhoea; children; probiotic

Mesh:

Year:  2015        PMID: 25653151     DOI: 10.3920/BM2014.0086

Source DB:  PubMed          Journal:  Benef Microbes        ISSN: 1876-2883            Impact factor:   4.205


  12 in total

1.  AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders.

Authors:  Geoffrey A Preidis; Adam V Weizman; Purna C Kashyap; Rebecca L Morgan
Journal:  Gastroenterology       Date:  2020-06-09       Impact factor: 22.682

2.  Probiotics in Disease Prevention and Treatment.

Authors:  Yuying Liu; Dat Q Tran; J Marc Rhoads
Journal:  J Clin Pharmacol       Date:  2018-10       Impact factor: 3.126

3.  Probiotics for treating acute infectious diarrhoea.

Authors:  Shelui Collinson; Andrew Deans; April Padua-Zamora; Germana V Gregorio; Chao Li; Leonila F Dans; Stephen J Allen
Journal:  Cochrane Database Syst Rev       Date:  2020-12-08

4.  Time Series Analysis of the Microbiota of Children Suffering From Acute Infectious Diarrhea and Their Recovery After Treatment.

Authors:  Ener C Dinleyici; Daniel Martínez-Martínez; Ates Kara; Adem Karbuz; Nazan Dalgic; Ozge Metin; Ahmet S Yazar; Sirin Guven; Zafer Kurugol; Ozden Turel; Mehmet Kucukkoc; Olcay Yasa; Makbule Eren; Metehan Ozen; Jose Manuel Martí; Carlos P Garay; Yvan Vandenplas; Andrés Moya
Journal:  Front Microbiol       Date:  2018-06-12       Impact factor: 5.640

Review 5.  Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases.

Authors:  Karolina Kaźmierczak-Siedlecka; Jakub Ruszkowski; Mateusz Fic; Marcin Folwarski; Wojciech Makarewicz
Journal:  Curr Microbiol       Date:  2020-05-29       Impact factor: 2.188

6.  A meta-analysis of the effects of probiotics and synbiotics in children with acute diarrhea.

Authors:  Bo Yang; Ping Lu; Mei-Xuan Li; Xiao-Ling Cai; Wan-Yuan Xiong; Huai-Jing Hou; Xiao-Qin Ha
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

7.  Effect of microencapsulation on Saccharomyces cerevisiae var. boulardii viability in the gastrointestinal tract and level of some blood biochemical factors in wistar rats.

Authors:  Hassan Ghorbani-Choboghlo; Donya Nikaein; Ali-Reza Khosravi; Reza Rahmani; Zohreh Farahnejad
Journal:  Iran J Microbiol       Date:  2019-04

Review 8.  Probiotics in Medicine: A Long Debate.

Authors:  Elisavet Stavropoulou; Eugenia Bezirtzoglou
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

9.  Heterologous Expression of the Leuconostoc Bacteriocin Leucocin C in Probiotic Yeast Saccharomyces boulardii.

Authors:  Ran Li; Xing Wan; Timo M Takala; Per E J Saris
Journal:  Probiotics Antimicrob Proteins       Date:  2021-02       Impact factor: 4.609

10.  A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Saccharomyces boulardii in Infants and Children With Acute Diarrhea.

Authors:  Florian Mourey; Varun Sureja; Dharmeshkumar Kheni; Parthiv Shah; Devang Parikh; Unmesh Upadhyay; Milan Satia; Dhara Shah; Charlotte Troise; Amélie Decherf
Journal:  Pediatr Infect Dis J       Date:  2020-11       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.